We recapitulated previous results that GLP-1RA prescription was associated with a reduced risk of developing both nonneovascular and neovascular AMD in older adults with documented ophthalmology follow-up, the authors wrote
Who responds best to CagriSema Ideal candidates: Significant obesity (BMI 30-40+) Previously plateaued on GLP-1s alone Need maximum weight loss Good GI tolerability Metabolic syndrome or diabetes Commitment to long-term use Excellent responders: Higher baseline weight (more to lose) Good adherence to protocol Combine with diet/exercise Younger patients (better metabolism) No significant medication interactions May respond less optimally: Very low starting weight (BMI 30%): Nausea (most common) Decreased appetite (intended effect) Constipation Fatigue (especially first months) Common (10-30%): Vomiting (if nausea not managed) Diarrhea (alternating with constipation) Abdominal pain/discomfort Headache Dizziness Less common ( 40 with comorbidities Insurance covers surgery Want permanent solution Don't want ongoing injections Sourcing cagrilintide and semaglutide Obtaining these peptides requires understanding current availability
How long do you have to act
Additionally, both bafilomycin treatment and CIP4 KO led to a reduction in cytosolic Halo-Rac1 levels and impaired cell migration (Supplementary Fig
Abordaje de factores contribuyentes: Evaluar y tratar condiciones coexistentes que dificultan la prdida de peso: resistencia a la insulina, sndrome de ovario poliqustico, apnea del sueo, deficiencia de vitamina D (comn en Hashimoto) y trastornos del estado de nimo
What are GLP-1 clinical trials
